Luye Pharma Group Ltd.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
| Przychód (średnia) |
6,952.02 |
6,994.15 |
7,750.80 |
8,682.02 |
| Przychód Δ r/r |
0.00% |
0.61% |
10.82% |
12.01% |
| Przychód (min) |
6,799.56 |
6,938.28 |
7,562.84 |
8,311.95 |
| Przychód (max) |
7,091.93 |
7,103.61 |
7,985.90 |
9,052.09 |
| EBITDA (średnia) |
2,014.80 |
2,028.84 |
2,248.33 |
2,518.45 |
| EBIT (średnia) |
1,264.09 |
1,272.90 |
1,410.61 |
1,580.09 |
| EBIT % |
18.18% |
18.20% |
18.20% |
18.20% |
| Zysk netto (średni) |
787.32 |
567.16 |
808.01 |
1,041.51 |
| Zysk netto % |
11.33% |
8.11% |
10.42% |
12.00% |
| EPS (średnia) |
0.21 |
0.15 |
0.21 |
0.28 |
| Liczba analityków (Przychody) |
4 |
3 |
3 |
3 |
| Liczba analityków (EPS) |
3 |
3 |
3 |
3 |
| symbol |
2186.HK |
2186.HK |
2186.HK |
2186.HK |